Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 62; no. 1; p. 21
• Main Authors: Dooley, Kelly E, Sayre, Patrick, Borland, Julie, Purdy, Elizabeth, Chen, Shuguang, Song, Ivy, Peppercorn, Amanda, Everts, Stephanie, Piscitelli, Stephen, Flexner, Charles
• Format: Journal Article
• Language: English
• Published: United States 01.01.2013
• Subjects: Adult; Antitubercular Agents - administration & dosage; Antitubercular Agents - adverse effects; Antitubercular Agents - pharmacokinetics; Cross-Over Studies; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring - administration & dosage; Heterocyclic Compounds, 3-Ring - adverse effects; Heterocyclic Compounds, 3-Ring - pharmacokinetics; HIV Integrase Inhibitors - administration & dosage; HIV Integrase Inhibitors - adverse effects; HIV Integrase Inhibitors - pharmacokinetics; Human Experimentation; Humans; Male; Middle Aged; Rifabutin - administration & dosage; Rifabutin - adverse effects; Rifabutin - pharmacokinetics; Rifampin - administration & dosage; Rifampin - adverse effects; Rifampin - pharmacokinetics

Cotreatment of tuberculosis (TB) and HIV among coinfected patients is now the standard of care. Rifampin (RIF) is a standard part of TB treatment but is a potent inducer of drug metabolizing enzymes. This study evaluated the effect of RIF or rifabutin (RBT) on the pharmacokinetics of the investigati...